BHVN Stock Recent News
BHVN LATEST HEADLINES
Shares of early-stage biotech stocks, including Biohaven (BHVN -6.50%), Recursion Pharmaceuticals (RXRX -4.92%), and CRISPR Therapeutics (CRSP -2.05%), plunged in March, with the stocks down 35.3%, 29.6%, and 22.5%, respectively, according to data from S&P Global Market Intelligence.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd - BHVN
NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd (“Biohaven” or the “Company”) (NYSE: BHVN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, NY / ACCESS Newswire / March 19, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biohaven Ltd. ("Biohaven" or "the Company") (NYSE:BHVN).
NEW YORK, NY / ACCESS Newswire / March 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biohaven Ltd. ("Biohaven" or "the Company") (NYSE:BHVN).
NEW YORK, NY / ACCESS Newswire / March 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biohaven Ltd. ("Biohaven" or "the Company") (NYSE:BHVN).
NEW YORK, NY / ACCESS Newswire / March 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biohaven Ltd. ("Biohaven Ltd.
NEW HAVEN, Conn. , Oct. 1, 2024 /PRNewswire/ -- Biohaven Ltd.
The heavy selling pressure might have exhausted for Biohaven Ltd. (BHVN) as it is technically in oversold territory now.
BridgeBio stock collapsed when acoramidis failed a pivotal trial, but follow-up data on the way could allow the program, and the stock, to redeem itself. Biohaven shares could shoot higher if the U.S. Food and Drug Administration accepts the company's latest new drug application.